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Abstract
Background: The Vegetative and Minimally Conscious States (VS; MCS) are characterized by absent or highly
disordered signs of awareness alongside preserved sleep-wake cycles. According to international diagnostic
guidelines, sleep-wake cycles are assessed by means of observations of variable periods of eye-opening and eye-
closure. However, there is little empirical evidence for true circadian sleep-wake cycling in these patients, and there
have been no large-scale investigations of the validity of this diagnostic criterion.
Methods: We measured the circadian sleep-wake rhythms of 55 VS and MCS patients by means of wrist
actigraphy, an indirect method that is highly correlated with polysomnographic estimates of sleeping/waking.
Results: Contrary to the diagnostic guidelines, a significant proportion of patients did not exhibit statistically
reliable sleep-wake cycles. The circadian rhythms of VS patients were significantly more impaired than those of
MCS patients, as were the circadian rhythms of patients with non-traumatic injuries relative to those with traumatic
injuries. The reliability of the circadian rhythms were significantly predicted by the patients’ levels of visual and
motor functioning, consistent with the putative biological generators of these rhythms.
Conclusions: The high variability across diagnoses and etiologies highlights the need for improved guidelines for
the assessment of sleep-wake cycles in VS and MCS, and advocates the use of actigraphy as an inexpensive and
non-invasive alternative.
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Background
The Vegetative State (VS) or Unresponsive Wakefulness
Syndrome (UWS [1]) is thought to reflect the dissocia-
tion of the two primary components of consciousness -
awareness and wakefulness [2,3]. A common tool for
the assessment of awareness is the Coma Recovery Scale
Revised [4] (CRS-R) which includes subscales designed
to assess a range of functions, including auditory, visual,
motor, verbal, communication and arousal. A brain-
injured patient is considered to possess awareness if
they produce non-reflexive responses to stimulation,
such as tracking an object that is moving in front of the
eyes, or following a verbal command. Patients in the VS
do not produce non-reflexive behavior and are, there-
fore, considered to lack awareness [5,6]. Patients in the
Minimally Conscious State (MCS) exhibit some repro-
ducible but inconsistent signs of awareness, although
communication remains absent [6,7].
Wakefulness, on the other hand, is thought to be pre-
served in both VS and MCS patients. According to the
standards for VS and MCS outlined by the Multi-Society
Task Force for Permanent Vegetative State [5] and the
Royal College of Physicians [6], ‘wakefulness’ refers to
the presence of typically cycling periods of eye-closure
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and eye-opening that give the appearance of sleep-wake
cycles. While a great deal of behavioral and neuroima-
ging research has focused on the assumption of una-
wareness in these patients [4,8-10], very little is known
regarding the assumption of preserved sleep-wake
rhythms.
A typical sleep-wake cycle follows a circadian rhythm,
with a period of between 19- and 28-hours [11]. Electro-
encephalography (EEG), in combination with other phy-
siological measures as part of polysomnography, is the
gold-standard approach for the assessment of sleep-
wake cycles [12]. However, the results of the limited
EEG investigations of circadian sleep-wake cycling in VS
and MCS patients are inconsistent with the assumption
of preserved wakefulness. Landsness et al. [13] observed
sleep-wake-like changes in the EEG of six MCS patients
across one day, while the EEG of five VS patients
remained unchanged between periods of eye-opening
and eye-closure. Isono et al. [14] also reported an
absence of EEG sleep-wake changes in 4 out of 12 VS
patients. High variability has also been observed in other
physiological circadian rhythms in VS and MCS, includ-
ing body temperature and hormone levels [15,16], blood
pressure and heart rate [16,17], and sleep-related erec-
tions [18]. Circadian-like variations in arousal have also
been reported in both VS and MCS patients, as indexed
by fluctuating behavioral abilities across the day [19].
Bekinschtein et al. [20] observed well-formed circadian
rhythms in the body temperatures of two VS patients
with traumatic brain injuries (TBI), but absent rhythms
in three VS patients who had sustained non-traumatic
brain injuries (non-TBI), indicating the potential rela-
tionship between etiology and circadian rhythms. It
appears, therefore, that, contrary to the diagnostic
guidelines describing these conditions, a great deal of
variability exists both within and across VS and MCS
patient groups with regard to the relative preservation
of circadian rhythms.
An indirect and inexpensive approach to detecting cir-
cadian sleep-wake cycles from large numbers of patients
is wrist actigraphy, in which a wrist-mounted device is
used to record the frequency and amplitude of motor
activity [12]. This method is known to correlate well
with polysomnographic measurements of sleep and
wakefulness in healthy individuals, as well as non-ambu-
latory patients, such as those with C5 to C7 tetraplegia
[21-23]. A number of algorithms have been developed
in order to produce minute-to-minute estimations of
sleeping/waking from short-term variations in actigraphy
data in healthy individuals. Broadly, these algorithms
judge an individual to be awake or asleep at a given
sample point by weighting the amount of movement in
a number of preceding sample points by a set of prede-
fined constants. Such approaches have reported between
88 and 97% concordance with polysomnography in
healthy individuals (see [21] for a full review). However,
none of these approaches have been validated with VS
or MCS patients by means of concurrent polysomnogra-
phy and actigraphy recordings. Nevertheless, a circadian
sleep-wake rhythm - that is, more activity during waking
hours and less activity during sleeping hours - can be
readily identified from raw actigraphy recordings, and
makes fewer assumptions than these un-validated algo-
rithms (for example, [24,25]). In the only article to
report actigraphy-based assessments of sleep-wake
rhythms in VS, Bekinschtein et al. [26] described a
greater deterioration in the circadian rhythmicity evident
in the actigraphy of one VS patient relative to an MCS
patient. De Weer et al. [27] also reported day-night var-
iation in the amount of movement (as measured by acti-
graphy) in two TBI MCS patients, but not in a non-TBI
MCS patient. However, in neither of these studies was
circadian rhythmicity examined statistically.
In order to investigate the relative preservation of cir-
cadian sleep-wake rhythmicity in patients in the VS and
MCS, we recorded wrist actigraphy from 55 patients (18
VS, 37 MCS) across four days, and subjected the data to
cosinor rhythmometry analyses (see Methods), a stan-
dard statistical approach for circadian rhythm identifica-
tion. By definition, all of these patients are considered to
possess circadian sleep-wake cycles [5-7]. In keeping
with the studies described above, however, we expected
to see variability in the extent to which circadian sleep-
wake rhythms were preserved across patients as a func-
tion of etiology (TBI vs. non-TBI) and diagnosis (VS vs.
MCS). We also predicted significant relationships
between the behavioral profiles of these patients - as
indexed by their CRS-R subscales - and the relative pre-
servation of their circadian sleep-wake rhythms.
Methods
Patients
Fifty-five patients were recruited from the University
Hospital of Liège, Belgium. Actigraphy recordings were
made for at least four days. All patients were VS or
MCS. During their admission, all patients were manually
turned in their beds four times per day. No patient had
skin pressure sores that required more frequent manual
turning. No patient required mechanical ventilation. All
patients were admitted as part of the same research pro-
tocol, and completed the same tasks across each day, for
example, behavioral tests, positron emission tomography
(PET), and magnetic resonance imaging (MRI). Across
their admission, all patients were assessed multiple
times with the CRS-R [4]. The highest CRS-R score and
diagnosis across this period are shown in Table 1, along
with other demographic information. In total, 18 VS
patients (mean age 38.0, SD 14.8; 7 TBI) and 37 MCS
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Table 1 Demographics and circadian rhythm fits for all patients.
Patient ID Gender Age (Years) Post-Ictus (Months) Diagnosis Etiology CRS-R Mesor Acrophase Amplitude Sig. Fit?
1 M 53 40 MCS Non-TBI 11 9.56 16:57 6.70 Yes
2 M 31 22 MCS Non-TBI 13 8.67 21:44 10.46 Yes
3 W 30 78 MCS Non-TBI 9 15.84 15:45 13.58 Yes
4 M 31 16 MCS Non-TBI 7 5.51 19:27 4.63 Yes
5 M 27 50 MCS Non-TBI 9 31.01 15:43 9.94 No
6 W 36 17 MCS Non-TBI 13 21.25 19:10 15.87 Yes
7 M 34 35 MCS Non-TBI 12 26.40 17:35 28.34 Yes
8 W 63 3 MCS Non-TBI 13 6.32 16:36 6.77 Yes
9 M 57 12 MCS Non-TBI 7 12.89 17:26 9.40 Yes
10 M 66 2 MCS Non-TBI 10 34.18 22:25 26.00 Yes
11 M 11 48 MCS Non-TBI 13 32.40 19:05 35.79 Yes
12 W 43 3 MCS Non-TBI 6 9.12 17:49 8.76 Yes
13 W 34 256 MCS Non-TBI 12 20.63 18:40 15.36 Yes
14 M 30 106 MCS TBI 14 49.20 20:18 41.91 Yes
15 W 21 1 MCS TBI 10 17.23 17:57 12.52 Yes
16 M 46 17 MCS TBI 11 42.80 22:46 48.47 Yes
17 M 30 27 MCS TBI 10 20.71 20:12 17.98 Yes
18 M 30 13 MCS TBI 9 54.24 17:16 22.60 Yes
19 M 24 10 MCS TBI 10 114.11 18:50 65.35 Yes
20 W 75 9 MCS TBI 9 8.57 17:06 9.55 Yes
21 W 34 99 MCS TBI 12 18.22 15:46 6.64 No
22 W 27 41 MCS TBI 11 15.02 23:05 16.01 Yes
23 M 24 88 MCS TBI 11 18.54 19:49 14.62 No
24 M 44 287 MCS TBI 9 5.25 19:37 4.83 Yes
25 W 30 4 MCS TBI 9 10.41 17:29 13.41 Yes
26 M 34 33 MCS TBI 8 27.22 18:30 27.89 No
27 M 23 10 MCS TBI 10 8.47 16:38 7.74 Yes
28 M 27 37 MCS TBI 13 40.74 20:53 34.18 Yes
29 M 61 4 MCS TBI 10 21.80 21:41 19.72 Yes
30 M 24 24 MCS TBI 11 88.98 22:18 56.45 No
31 M 23 66 MCS TBI 16 14.09 17:24 18.96 No
32 M 21 38 MCS TBI 8 10.09 15:55 7.06 Yes
33 M 30 109 MCS TBI 10 35.15 20:26 21.87 Yes
34 W 24 21 MCS TBI 10 15.45 18:58 18.08 Yes
35 M 36 4 MCS TBI 11 6.49 16:10 5.53 Yes
36 M 65 22 MCS TBI 7 11.30 16:13 15.14 Yes
37 M 21 5 MCS TBI 7 9.69 13:41 7.90 Yes
38 W 66 0 VS Non-TBI 3 4.56 15:43 5.24 Yes
39 M 35 220 VS Non-TBI 7 11.01 19:20 10.24 Yes
40 M 30 24 VS Non-TBI 6 25.15 15:28 14.67 Yes
41 W 48 15 VS Non-TBI 5 8.50 17:14 10.53 Yes
42 W 67 45 VS Non-TBI 5 15.46 18:29 12.23 Yes
43 M 53 1 VS Non-TBI 5 9.53 16:53 7.92 Yes
44 M 34 17 VS Non-TBI 7 5.68 17:43 2.79 Yes
45 W 41 56 VS Non-TBI 5 14.39 17:35 14.49 Yes
46 W 48 4 VS Non-TBI 4 4.78 20:02 3.44 No
47 M 48 30 VS Non-TBI 6 2.31 17:19 2.03 Yes
48 M 36 66 VS Non-TBI 5 7.34 17:40 6.88 Yes
49 M 34 43 VS TBI 6 10.84 13:47 7.87 Yes
50 W 30 18 VS TBI 4 6.49 16:56 8.07 Yes
51 M 21 7 VS TBI 7 8.58 18:15 8.29 Yes
52 M 35 290 VS TBI 8 57.65 23:10 36.56 No
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patients (mean age 35.7, SD 15.2; 24 TBI) contributed
data to the study. There was no significant difference in
the proportions of each etiology contributing to the VS
and MCS groups. Two two-way ANOVAs with factors
of diagnosis (VS, MCS) and etiology (TBI, non-TBI)
conducted on age (in years) and months post-ictus
revealed only a reliable main effect of etiology on age
(F(1, 51) = 10.363, P <.01) reflecting the older average
age of non-TBI patients. Informed consent was obtained
from the patients’ surrogate decision makers. The Ethics
Committee of the University and University Hospital of
Liège provided ethical approval for the study.
Procedure
Actigraphy recordings were made with a Philips Acti-
watch Spectrum (Philips Healthcare, Best, Brabant, The
Netherlands) attached to the wrist with the highest
range of movement (never the hemiplegic side) for a
minimum of four days, sampled in one-minute epochs.
In order to normalize across patients, only the first four
days of actigraphy data were included in the analyses for
those patients who were admitted for longer than four
days. The first two hours of data were also excluded to
avoid initial artifacts from attachment of the Actiwatch.
Circadian rhythm analyses
Cosinor rhythmometry analyses [28] were performed on
each patient’s dataset individually. This approach uses the
least squares method to fit a sine wave with a period of
24 hours to the raw actigraphy data [11,12,28]. The rhyth-
micity of the fit can be described by three parameters: the
amplitude, the acrophase, and the mesor. The amplitude
of the fit refers to half the distance between the peak and
the trough of the fitted wave - in effect describing the
amount of movement produced during periods of activity.
The acrophase describes the point in the cycle at which
activity is maximal. Finally, the mesor (an acronym for
midline-estimating statistic of rhythm [28]) describes the
rhythm-adjusted mean of the wave, or the value around
which the fitted wave oscillates. For equidistant data sam-
ples (as employed here), the mesor is equivalent to the
arithmetic mean of the fitted wave, or the average amount
of activity produced across the recording period. The
goodness-of-fit of the wave - that is, the statistical reliabil-
ity of the circadian rhythm - can also be determined by
means of a zero-amplitude F-test [28].
In order to control for over-fitting of noise to the sine
wave, this goodness-of-fit P-value was subsequently sub-
jected to a permutation test. Specifically, a set of sine
waves with periods ranging in 10-minute intervals from
6 hours to 48 hours were fit to the data (excluding
rhythms between 19 and 28 hours since these are
defined as circadian periods; see Introduction [11]). The
P-values from these 200 zero-amplitude tests were then
used to form a surrogate distribution to test the hypoth-
esis that a 24-hour rhythm does not fit the data better
than a non-circadian period. When the goodness-of-fit
P-value associated with the 24-hour rhythm fell below
the smallest 5% of surrogate P-values, the circadian
rhythm was considered to be significant at P <.05.
Results
A total of 46 out of the whole group of 55 patients (84%)
exhibited significant 24-hour rhythms in their actigraphy
data after permutation testing. This proportion is signifi-
cantly lower than the diagnostic expectation that all
patients retain significant circadian rhythms (Fisher’s
Exact Test, P <.01). When separated according to diagno-
sis, 15/18 VS patients (83%) and 31/37 MCS patients
(84%) returned circadian rhythms that passed this statisti-
cal test. When separated according to etiology, 24/31 TBI
patients (77%) and 22/24 non-TBI patients (92%) exhib-
ited circadian rhythms. There was no significant effect of
diagnosis or etiology on the proportions of patients exhi-
biting circadian rhythms (Fisher’s Exact Tests, all P >.14).
While age significantly differed across etiologies, it did
not significantly correlate with any of the four rhythmi-
city variables (mesor, amplitude, acrophase or goodness-
of-fit, as indexed by the log-transformed zero-amplitude
F-ratio).
VS versus MCS patients
Four one-way ANOVAs with diagnosis (VS, MCS) as
the factor of interest revealed the main effects of mesor
(F(1,54) = 4.441, P <.05), amplitude (F(1,54) = 6.819,
P <.05), and goodness-of-fit (F(1,54) = 16.517, P <.001),
but not acrophase. Together these reflect the greater
average amount of movement across the four days
(mesor), the greater amount of movement during peri-
ods of activity (amplitude), and greater statistical relia-
bility of the circadian rhythms (goodness-of-fit) of MCS
patients relative to VS patients (see Figure 1).
Table 1 Demographics and circadian rhythm fits for all patients. (Continued)
53 M 21 8 VS TBI 6 9.95 19:22 6.45 Yes
54 M 13 1 VS TBI 6 5.78 21:24 3.12 No
55 M 25 15 VS TBI 5 10.02 16:19 9.05 Yes
The final column indicates whether the circadian rhythm fit was significant or not. MCS, Minimally Conscious State; TBI, Traumatic Brain Injury; VS, Vegetative
State
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Due to the high inter-correlations between these three
significant rhythmicity variables (all absolute r > .33), all
three variables were entered into a backward stepwise
logistic regression in order to determine their relation-
ships with diagnosis, over and above the effects of
the other two variables. This regression retained only
goodness-of-fit in the model as a significant predictor
(Wald = 10.189, Beta (SE) = -2.043 (.640), P < .01), indi-
cating significantly weaker circadian rhythms in VS
patients relative to MCS patients, regardless of the
amount of movement produced by these patients.
Traumatic versus non-traumatic brain injury
Four one-way ANOVAs with etiology (TBI, non-TBI) as
the factor of interest revealed the main effects of ampli-
tude (F(1,54) = 4.299, P < .05) and goodness-of-fit
(F(1,54) = 4.226), P < .05), but not mesor or acrophase.
These effects reflect the greater amount of movement
during periods of activity (amplitude) and the greater
statistical reliability of the circadian rhythms (goodness-
of-fit) of TBI patients relative to non-TBI patients.
As with the analyses across diagnosis, due to the high
inter-correlations between the two significant rhythmi-
city variables, both were entered into a backward step-
wise logistic regression in order to determine their
relationships with etiology, over and above the effect of
the other variable. This regression retained neither vari-
able as a significant predictor, likely due to the weak
effects of etiology on these variables (contrast F-values
above with those in the analyses across diagnosis).
Relationship between rhythmicity and behavioral profile
Four backward linear regressions were conducted on the
four rhythmicity variables with the six subscales of the
CRS-R as predictors. Diagnosis was also included as a
predictor since the higher scores on each subscale are
also more likely to be associated with MCS and the lower
scores with VS. The motor sub-scale was found to signifi-
cantly predict mesor (F(1,54) = 7.792, P < .01, B(SE) =
6.174 (2.212), P < .01) and amplitude (F(2,54) = 6.178, P <
.01, B(SE) = 3.462 (1.453), P < .05). The visual sub-scale
was found to significantly predict acrophase (F(1,54) =
4.636, P < .05, B(SE) = -.108 (.050), P < .05), and both the
visual and motor subscale together were found to predict
goodness-of-fit (F(2,54) = 16.487, P < .001, B-visual(SE) =
.208 (.055), P < .001, B-motor(SE) = .225 (.071), P < .005).
Discussion
On the basis of periodic eye-opening and eye-closure,
patients in the VS and MCS are considered to have pre-
served circadian sleep-wake rhythms [5,6]. However, by
means of an indirect measure of sleep-wake rhythmicity
- wrist actigraphy - we have shown that a significant
proportion of these patients do not exhibit statistically
reliable circadian sleep-wake rhythms. The observed
variability across patients is consistent with previous
smaller studies of circadian rhythmicity in VS and MCS
(see Background), and is the first evidence from a large-
scale study of sleep-wake cycling using the inexpensive
and non-invasive method of wrist actigraphy.
While there was no significant difference in the propor-
tion of patients exhibiting significant sleep-wake rhythms
between VS and MCS patients, the goodness-of-fit of the
circadian rhythms in the data of MCS patients were signif-
icantly higher than those of the VS patients (see Figure 1).
This result indicates that the circadian sleep-wake cycles
of MCS patients were significantly more statistically reli-
able than those of VS patients. Importantly, this remained
Figure 1 Actigraphy data from four representative patients. Each panel shows intensity of activity across each recording day. Red lines
indicate the fit of the circadian rhythm. Note the periodic structure of the activity of the two patients with significant rhythms (left), compared
with those without (right). Patients 19, 21, 52 and 45 are shown (clockwise from top-left). Log activity data smoothed across five minutes is
plotted for clarity of visualization.
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true when taking into account the morphology of the
rhythm (that is, its mesor and amplitude), indicating that
the effect of diagnosis on the statistical reliability of the
circadian rhythms is not driven by simple differences in
the amount that a patient moves, but rather reflects differ-
ences in the circadian rhythmicity with which this move-
ment occurs.
A master biological clock in the hypothalamic supra-
chiasmatic nuclei (SCN) is considered to maintain the
timing of circadian rhythms. The SCN in turn modu-
lates the activity of the ascending reticular activating
system (ARAS) - a circuit of subcortical nuclei responsi-
ble for promoting wakefulness (see [29] for a review).
One region of the ARAS - the central thalamus - is
known to be crucial for the regulation of arousal and
has been linked to the disorders of consciousness exhib-
ited by VS and MCS patients [30]. Indeed, the extent of
atrophy in this region of the thalamus has been asso-
ciated with the degree of disability exhibited by these
patients [31]. More broadly, greater thalamic atrophy
has been observed in VS patients relative to MCS
patients using in vivo diffusion tensor imaging [32]
(DTI). The weaker circadian sleep-wake rhythms
observed in the VS patients in the current study are,
therefore, entirely consistent with these differential pat-
terns of damage to the thalamus.
Etiology was also shown to have a small effect on the
amount that patients moved during periods of activity
(amplitude) and the statistical reliability of the circadian
rhythm (goodness-of-fit). Similarly, Bekinschtein et al.
[20] observed reliable circadian temperature rhythms in
only TBI VS patients, but not in non-TBI patients, while
De Weer et al. [27] detected sleep-wake activity changes
in only TBI MCS patients. The primary neuropathology
associated with TBI is diffuse axonal injury with relative
preservation of the cortex, while non-TBI involves more
widespread damage to the cortex and basal ganglia
[33-39]. The greater impairment of circadian rhythms in
non-TBI patients relative to TBI patients reported here
is, therefore, consistent with the general patterns of neu-
ropathology associated with the two etiologies. Indeed,
mouse models of hypoxic brain injury have been shown
to result in impaired sleep-wake cycling [40].
Significant relationships were also observed between
the behavioral profiles of the patients - as indexed by
their CRS-R sub-scales - and aspects of their circadian
rhythmicities. A significant positive relationship was
found between the motor subscale and the mesor and
amplitude of the rhythm. The motor subscale of the
CRS-R is scored from flaccid motor tone at its lowest, to
object manipulation and automatic motor responses at
its highest (before emergence from MCS). Since wrist
movements were used to indirectly measure the circadian
rhythms, it is unsurprising that greater amounts of
movement exhibited by patients across the recording per-
iod (mesor, amplitude) are related to their overall abilities
to produce motor output during behavioral assessments.
This result suggests the need for caution in the use of
actigraphy for assessing circadian sleep-wake rhythms
since they rely on motor output for a rhythm to be
detected. Nevertheless, our analyses have demonstrated
that significant changes in the statistical reliability of the
rhythms across diagnoses are not dependent on the
amount of movement produced, suggesting that actigra-
phy can be used to assess the statistical reliability of cir-
cadian sleep-wake cycles, regardless of the degree of
activity exhibited by the patients.
A combination of the visual and motor subscales signifi-
cantly predicted the goodness-of-fit of the circadian
rhythms. The visual subscale score describes behaviors
from absent visual startle at its lowest, through fixation
and pursuit, to object recognition at its highest. This rela-
tionship is of particular interest since the master clock for
circadian rhythms, the SCN, is itself timed by light inputs
from the retina during the day, as well as melatonin from
the pineal gland at night [29]. The more purposeful eye-
movements of those scoring high on the visual subscale
may allow for differing levels of light to reach the retina -
perhaps through a greater ability to orient toward light or
to maintain eye-opening for longer periods - and, conse-
quently, result in a strengthening of the rhythm via the
SCN. The predictive value of the visual subscale could,
therefore, be considered to be consistent with our under-
standing of the biological generators of sleep-wake rhyth-
micity. This conclusion is necessarily speculative, however,
since it is unclear whether high visual functioning is asso-
ciated with a greater degree of orientation toward light or
longer periods of eye-opening. Further investigation of this
relationship will contribute to our understanding of the
exogenous cues that drive circadian rhythms in VS/MCS
patients.
A significant relationship was also found between the
visual subscale of the CRS-R and the acrophase (time of
maximal activity) of the rhythm, over and above the con-
tribution of the other CRS-R subscales, or of the diagno-
sis of the patient. The relationship with acrophase
reflects the tendency for patients with higher visual func-
tioning to be most active later in the afternoon than
patients with lower visual functioning (Visual Score >= 1,
Mean acrophase (SD) 18:20 (three hours); Visual Score =
0, Mean acrophase (SD) 17:20 (two hours)). Consistent
with this observation, exposure to higher levels of light
has been associated with later peaks of activity in institu-
tionalized individuals [41,42]. However, the activity peaks
of healthy individuals occur earlier in the day than those
observed in the patients here, typically between approxi-
mately 13:30p.m. and approximately 16:00p.m. [24].
It has been observed that the levels of light experienced
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by institutionalized patients are considerably lower than
those of non-institutionalized individuals [42,43], and
since the patients in the current study were residing on a
hospital ward during the recording period, it is likely they
were exposed to abnormally fluctuating levels of light
compared with healthy individuals. Unfortunately, we
were unable to record light levels alongside actigraphy;
however, future studies investigating their contribution
to the timing of activity of VS and MCS patients will be
invaluable.
Since we inferred the circadian rhythms of patients
from wrist actigraphy, it is likely that the recordings
contain some levels of exogenous activity, perhaps from
nurses moving the patient from bed to chair. Since
these patients were all admitted to the same ward of the
University Hospital of Liège as part of the same research
protocol, they all received equivalent levels of care and
were involved in the same assessments throughout the
day - for example, behavioral tests, PET and MRI. As a
result, the potential exogenous noise in the data would
then be equally distributed across all patients. Our con-
clusions regarding the effects of diagnosis, etiology and
behavioral profile on sleep-wake cycles, therefore, would
remain valid despite this potential confound. The use of
simultaneous video-recordings would allow for the
exclusion of activity that is generated exogenously and
would further validate our findings.
Some prescribed medications may also have an effect
on actigraphy-detected circadian rhythms. For example,
treatment for spasticity (for example, with baclofen) is
common in VS/MCS patients and may increase the
amount of movement that will be detected with actigra-
phy, while psychoactive medications (for example,
amantadine) may also serve to exogenously modulate a
patient’s level of arousal. Caution in this regard is not
limited to actigraphy, however, since psychoactive medi-
cations will also alter the resting EEG of a patient,
thereby modulating the level of wakefulness that will be
inferred from polysomnography. Due to differences in
the wishes of families and physicians, a wide variety of
medications are prescribed to VS and MCS patients (see
Table 2 for details). As a result, it is not possible to sta-
tistically control for each of these drugs individually, nor
for their many interactions. Nevertheless, there is no
reason to believe that prescribed medications would sys-
tematically differ between VS and MCS groups due to
the paucity of treatment recommendations for all
patients with disorders of consciousness ([44]). Future
controlled clinical trials are needed in order to provide
insights into the effects of specific medications not only
on circadian rhythmicity, but also on VS/MCS patient
outcome in general.
A final caveat is that the apparent absence of reliable
circadian rhythms in some of our patients may be a
Table 2 Patient etiology and prescribed daily
medications.
Patient ID Specific etiology Daily medication dosage
1 Anoxia 1 × Clonazepam 2 mg
1 × Phenytoin 100 mg
1 × Clopidogrel 75 mg
1 × Acetylcysteine 600 mg
3 × Baclofen 25 mg
3 × Levetiracetam 500 mg
2 Anoxia 1 × Amantadine 100 mg
2 × Clonidine 150 mg
1 × Bisopropol 2.5 mg
1 × Paroxetine 20 mg
1 × Tetrazepam 50 mg
1 × Acetylcysteine 600 mg
3 Anoxia 2 × Lamotrigine 50 mg
1 × Levetiracetam 1,000 mg
3 × Diazepam 5 mg
3 × Baclofen 25 mg
1 × Esomeprazole 20 mg
1 × Domperidome 10 mg
4 Anoxia 1 × Vancomycin 2,000 mg
4 × Piperacillin 4,000 mg
4 × Amikacin 1,000 mg
1 × Enoxaparin Sodium 50 mg
3 × Paracetamol 1,000 mg
1 × Diazepam 10 mg
3 × Baclofen 15 mg
1 × Acetylcysteine 600 mg
5 Anoxia 3 × Valproic Acid 40 ml
3 × Diazepam 10 mg
2 × Terbutaline 5 mg
3 × Baclofen 10 mg
3 × Dantrolene 25 mg
1 × Enoxaparin Sodium 40 mg
2 × Fluconazole 50 mg
1 × Aspirin 160 mg
6 Anoxia 1 × Amantadine 100 mg
1 × Zolpidem 10 mg
1 × Esomeprazole 20 mg
1 × Trihexyphenidyl 4 mg
7 Tumor/Hemorrhage 2 × Lamotrigine 100 mg
1 × Aspirin 80 mg
1 × Omeprazole 20 mg
1 × Escitalopram 10 mg
8 Anoxia 1 × Aspirin 100 mg
3 × Tizanidine 4 mg
1 × Enoxaparin Sodium 40 mg
1 × Omeprazole 20 mg
9 Anoxia 1 × Esomeprazole 20 mg
2 × Valproic Acid 500 mg
10 Anoxia 1 × Esomeprazole 20 mg
3 × Valproic Acid 2 ml
2 × Levetiracetam 7.5 ml
1 × Enoxaparin Sodium 40 mg
11 Anoxia 3 × Baclofen 10 mg
1 × Omeprazole 10 mg
4 × Domperidone 1 mg
2 × Clonazepam 1 mg
12 Aneurysm 1 × Enoxaparin Sodium 40 mg
13 Anoxia 2 × Carbamazepine 200 mg
14 Trauma 1 × Valproic Acid 500 mg
1 × Lansoprazole 20 mg
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Table 2 Patient etiology and prescribed daily medica-
tions. (Continued)
15 Trauma 1 × Phenobarbital 100 mg
3 × Baclofen 10 mg
16 Trauma 1 × Valproic Acid 500 mg
1 × Bisoprolol 5 mg
3 × Piracetam 1,200 mg
3 × Baclofen 25 mg
17 Trauma 1 × Omeprazole 20 mg
2 × Flecainide 100 mg
2 × Levetiracetam 10 ml
3 × Baclofen 10 mg
2 × Sodium Valproate 600 ml
1 × Clonazepam 2 mg
18 Trauma 1 × Escitalopram 10 mg
4 × Alprazolam 250 mg
1 × Trazodone 100 mg
1 × Prothipendyl 80 mg
19 Trauma 2 × Baclofen 10 mg
1 × Paracetamol 500 mg
1 × Esomeprazole 40 mg
2 × Levetiracetam 7.5 ml
20 Trauma 1 × Bisopropol 2.5 mg
1 × Pantoprazole 20 mg
2 × Tizanidine 2 mg
1 × Enoxaparin Sodium 40 mg
21 Trauma 2 × Ranitidine 150 mg
3 × Baclofen 25 mg
1 × Enoxaparin Sodium 40 mg
22 Trauma 3 × Baclofen 25 mg
2 × Tizanidine 4 mg
1 × Enoxaparin Sodium 20 mg
1 × Amantadine 50 mg
23 Trauma 3 × Baclofen 25 mg
3 × Domperidome 10 mg
2 × Clonazepam 2.5 mg
1 × Promethazine 16 mg
24 Trauma 1 × Amantadine 100 mg
2 × Baclofen 10 mg
1 × Esomeprazole 20 mg
1 × Tizanidine 4 mg
25 Trauma 2 × Valproic Acid 7.5 ml
1 × Lamotrigine 25 mg
3 × Baclofen 10 mg
2 × Esomeprazole 20 mg
1 × Enoxaparin Sodium 20 mg
26 Trauma 1 × Esomeprazole 40 mg
3 × Clonazepam 2 mg
3 × Paracetamol 1,000 mg
2 × Levetiracetam 500 mg
3 × Benserazide 250 mg
27 Trauma 1 × Acetylcysteine 600 mg
1 × Esomeprazole 20 mg
1 × Baclofen 25 mg
1 × Atenolol 50 mg
1 × Enoxaparin Sodium 40 mg
1 × Glycopyrrolate 10 mg
28 Trauma 1 × Amantadine 100 mg
1 × Paroxetine 20 mg
3 × Domperidone 10 mg
1 × Esomeprazole 20 mg
Table 2 Patient etiology and prescribed daily medica-
tions. (Continued)
29 Trauma 2 × Bisopropol 2.5 mg
1 × Esomeprazole 20 mg
1 × Amantadine 100 mg
3 × Metamizole 500 mg
3 × Meropenem 1,000 mg
3 × Ciprofloxacin 400 mg
30 Trauma 3 × Baclofen 25 mg
1 × Amantadine 100 mg
1 × Escitalopram 10 mg
1 × Enoxaparin Sodium 40 mg
31 Trauma 1 × Omeprazole 20 mg
1 × Ranitidine 300 mg
3 × Valproic Acid 2 ml
1 × Sertraline 2.5 mg
2 × Baclofen 5 ml
32 Trauma 2 × Carbamazepine 400 mg
33 Trauma 1 × Lansoprazole 30 mg
1 × Topiramate 150 mg
2 × Modafinil 100 mg
1 × Aniracetam 1,500 mg
34 Trauma 3 × Levetiracetam 500 mg
3 × Baclofen 10 mg
1 × Atenolol 50 mg
1 × Esomeprazole 20 mg
3 × Indometacin 50 mg
35 Trauma 2 × Ranitidine 150 mg
1 × Acetylcysteine 200 mg
3 × Baclofen 10 mg
1 × Escitalopram 10 mg
1 × Amantadine 100 mg
2 × Diclofenac 50 mg
1 × Enoxaparin Sodium 40 mg
36 Trauma 1 × Acetylcysteine 600 mg
1 × Esomeprazole 20 mg
1 × Baclofen 10 mg
37 Trauma 1 × Baclofen 10 mg
1 × Trazodone 25 mg
1 × Enoxaparin Sodium 40 mg
38 Anoxia 1 × Levetiracetam 3,000 mg
1 × Phenobarbital 100 mg
1 × Esomeprazole 40 mg
1 × Simvastatin 40 mg
1 × Aspirin 100 mg
1 × Escitalopram 10 mg
39 Anoxia 1 × Levothyroxine 25 mg
1 × Carbamazepine 200 mg
40 Anoxia 1 × Ranitidine 300 mg
3 × Phenobarbital 100 mg
3 × Baclofen 25 mg
5 × Lorazepam 2.5 mg
1 × Phenytoin 100 mg
41 Anoxia 1 × Amiodarone 200 mg
1 × Clopidogrel 75 mg
3 × Baclofen 25 mg
2 × Diltiazem 60 mg
1 × Trazodone 100 mg
1 × Lormetazepam 2 mg
2 × Prazepam 10 mg
1 × Enoxaparin Sodium 40 mg
2 × Acetylcysteine 400 mg
3 × Dantrolene 25 mg
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result of a lack of sensitivity of the actigraphy method,
rather than the true absence of those rhythms. While
wrist actigraphy has been validated for sleep assessment
in patients with C5 to C7 tetraplegia [23], these patients
are nevertheless capable of small but purposeful wrist
movements. Patients in the VS, however, are by defini-
tion unable to produce purposeful movements, although
spontaneous movements are common. Similarly, due to
the heterogeneity of brain injuries of these patients, it is
not clear whether the presence of actigraphy-detected
waking is necessarily indicative of concurrent cerebral
waking. Future validation of the relationship between
polysomnography and actigraphy measures of sleeping
and waking in VS and MCS patients is needed in order
to fully characterize the nature of their circadian
rhythms.
Conclusions
Our analyses indicate a greater impairment of circadian
sleep-wake cycling in patients in the VS compared with
those in the MCS, and in those with non-TBI compared
with TBI. The significant differences observed between
VS and MCS patients support the conclusion that these
are diagnostically distinct entities. However, they also
suggest that despite periods of eye-closure and eye-
opening, sleep-wake cycles are not necessarily present
despite the clinical criteria for these conditions [5-7].
Wrist actigraphy is considerably less expensive and less
invasive than other forms of sleep-wake monitoring and
may, therefore, provide a reliable means of determining
the extent to which these cycles are preserved in indivi-
dual patients. These recordings could also allow clini-
cians and researchers to identify the time of day in
which a patient is most active, in order to schedule
behavioral and/or neuroimaging assessments for a time
that maximizes the likelihood of detecting an appropri-
ate response (see [26]). Future validation of the relation-
ship between actigraphy and polysomnography measures
of sleeping/waking in VS and MCS patients will allow
for a more complete understanding of the physiological
nature of these circadian rhythms. Follow-up studies
will also determine the prognostic utility of wrist acti-
graphy for VS and MCS patients.
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Table 2 Patient etiology and prescribed daily medica-
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42 Aneurysm 1 × Bisopropol 5 mg
3 × Baclofen 10 mg
1 × Levothyroxine 50 mg
1 × Prednisolone 5 mg
43 Meningitis 1 × Moxifloxacin 500 mg
1 × Levetiracetam 500 mg
2 × Ranitidine 150 mg
1 × Enoxaparin Sodium 40 mg
44 Anoxia 2 × Levetiracetam 1,000 mg
1 × Phenytoin 500 mg
6 × Valproic Acid 6.5 ml
1 × Lorazepam 1 mg
1 × Ranitidine 300 mg
2 × Enoxaparin Sodium 60 mg
45 Anoxia 3 × Valproic Acid 600 mg
1 × Ranitidine 150 mg
46 Cardio-respiratory Arrest 2 × Acetylcysteine 200 mg
1 × Enoxaparin Sodium 60 mg
1 × Ranitidine 10 ml
47 Anoxia 1 × Atenolol 25 mg
2 × Modafinil 100 mg
48 Anoxia 3 × Baclofen 10 mg
1 × Diazepam 5 mg
1 × Prazepam 5 mg
2 × Omeprazole 20 mg
1 × Levocetirizine 10 mg
49 Trauma 3 × Dantrolene 100 mg
3 × Carbamazepine 200 mg
3 × Baclofen 25 mg
1 × Omeprazole 20 mg
1 × Enoxaparin Sodium 40 mg
50 Trauma 3 × Baclofen 25 mg
1 × Pantoprazole 20 mg
3 × Dantrolene 100 mg
1 × Enoxaparin Sodium 40 mg
51 Trauma 3 × Baclofen 25 mg
1 × Trazodone 100 mg
1 × Enoxaparin Sodium 40 mg
2 × Levetiracetam 5 ml
52 Trauma None
53 Trauma 4 × Paracetamol 500 mg
3 × Baclofen 10 mg
2 × Esomeprazole 20 mg
4 × Acetylcysteine 300 mg
54 Trauma 2 × Oxcarbazepine 450 mg
1 × Levetiracetam 5 ml
1 × Baclofen 25 mg
1 × Tizanidine 4 mg
55 Trauma 2 × Levetiracetam 100 mg
2 × Ranitidine 150 mg
2 × Lamotrigine 25 mg
3 × Baclofen 25 mg
1 × Enoxaparin Sodium 40 mg
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